




**CROHN'S
& COLITIS**
FOUNDATION



IBD INNOVATE™

PRODUCT DEVELOPMENT FOR CROHN'S & COLITIS

**The premier IBD product development
conference for therapeutics, diagnostics,
devices, and digital health.**

April 9-10, 2024

MassBio

**700 Technology Square, 5th Floor
Cambridge, MA 02139**

bit.ly/IBD-Innovate24



Welcome to IBD INNOVATE 2024!

The Crohn's & Colitis Foundation welcomes you to the premier IBD product development event highlighting novel therapeutics, diagnostics, devices, and digital health technologies with the potential to bring innovative solutions to benefit patients' health and quality of life.

Now in our sixth year, IBD Innovate's special focus in 2024 includes innovations in diagnostic tools, treatments for complications in IBD, therapeutics with novel mechanism of action, and the current venture capital environment specific to IBD products. You can also experience our poster session and some friendly competition we're introducing this year. Take advantage of the opportunity to learn, share, and collaborate at IBD Innovate 2024!

Organizing Committee



Tom Shehab, MD
Managing Partner
Arboretum Ventures



Andrés Hurtado-Lorenzo, PhD
Senior Vice President,
Translational Research & IBD Ventures
Crohn's & Colitis Foundation



Russell Wyborski, PhD
Director, IBD Ventures Investments
Crohn's & Colitis Foundation



Nicole Schwerbrock, PhD
Senior Manager,
IBD Ventures Investments
Crohn's & Colitis Foundation

Registration and Event Information



bit.ly/IBD-Innovate24

Social Media

Join the conversation on social media using hashtag **#IBDInnovate24**

Contact

Program-related inquiries:

Nicole Schwerbrock
Innovate24@crohnscolitisfoundation.org

Sponsorship-related inquiries:

Elise Ambrose
eambrose@crohnscolitisfoundation.org
or 646-745-4738

AGENDA

Day One: April 9, 2024

New products for IBD patients—What to expect next!

TIME	TITLE	SPEAKER	AFFILIATION
8:00–9:00 a.m.	Breakfast/Registration		
9:00–9:15 a.m.	Welcome: IBD Ventures & IBD Innovate	Andrés Hurtado-Lorenzo, PhD <i>Senior Vice President, Translational Research & IBD Ventures</i>	Crohn's & Colitis Foundation
KEYNOTE—SYNTHETIC BIOLOGY AND THE FUTURE OF IBD Moderator: Andrés Hurtado-Lorenzo, PhD			
9:15–10:00 a.m.	Synthetic biology and the future of IBD	Tim L. Lu, MD, PhD <i>Co-Founder and CEO</i>	Senti Bio
SESSION 1: New diagnostics for IBD		Company presentations	
10:00–10:15 a.m.	A liquid biopsy for assessing type and severity of inflammatory bowel disease via plasma microbial cell-free DNA	Shiv Kale, PhD <i>Director, Computational Biomarker Discovery</i>	Karius Inc.
10:15–10:30 a.m.	Developing a non-invasive breath test for IBD using volatile probes	Huw Alun Davies, PhD <i>Vice President of Business Development, Research Products, and Services</i>	Owlstone Medical
10:30–10:45 a.m.	Noninvasive stool RNA test approximates disease activity and predicts therapeutic response in patients with inflammatory bowel disease	Erica Barnell, MD, PhD <i>Co-Founder, Chief Medical Officer, Chief Science Officer</i>	Geneoscopy
10:45–11:10 a.m.	Q&A with speakers		
11:10–11:30 a.m.	Break/Networking		
KEYNOTE—TREATMENTS FOR INTESTINAL FIBROSIS Moderator: Nicole Schwerbrock, PhD			
11:30 a.m.–12:15 p.m.	Treatments for intestinal fibrosis	Florian Rieder, MD <i>Vice Chair, Department of Gastroenterology, Hepatology, and Nutrition</i>	Cleveland Clinic
SESSION 2: Treatments for complications in IBD		Company presentations	
12:15–12:30 p.m.	MBF-118. A first-in-class therapy for fibrosis in Crohn's disease	Richard Roberts, PhD <i>Chief Scientific Officer</i>	Medibiofarma
12:30–12:45 p.m.	Cell therapy for fistulizing Crohn's disease: Current state and future directions	Amy Lightner, MD <i>Professor of Surgery</i>	Scripps Research Institute

AGENDA

Day One: April 9, 2024

TIME	TITLE	SPEAKER	AFFILIATION
12:45–1:00 p.m.	A personalized approach to study intestinal fibrosis using human intestinal organoids derived from induced pluripotent stem cells	Robert Barrett, PhD <i>Associate Professor in Medicine</i>	Cedars-Sinai
1:00–1:20 p.m.	Q&A with speakers		
1:20–2:15 p.m.	Lunch and networking		
2:15–2:45 p.m.	Patient Speaker	Jordyn Burger	Patient Stakeholder
SESSION 3: Therapeutics with novel mechanism of action		Company presentations	Moderator: Russ Wyborski, PhD
2:45–3:00 p.m.	Advancing PALI-2108: Discovery to strategic positioning	Christophe Mellon, PhD <i>Chief Executive Officer, Giant Pharma</i> Mitchell Jones, MD, PhD <i>Chief Medical Officer, Palisade Bio</i>	Giant Pharma & Palisade Bio
3:15–3:30 p.m.	LRH-1 modulation: Targeted immune modulation for the treatment of inflammatory bowel disease	Eric Ortlund, PhD <i>Co-Founder</i>	Allonix Therapeutics
3:30–3:45 p.m.	A novel agent targeting neutrophils: Advancing the treatment of IBD	Renu Gupta, MD <i>Chief Medical Officer</i>	Adiso Therapeutics
3:45–4:05 p.m.	Q&A with speakers		
4:05–6:00 p.m.	Poster Session/Networking/Reception		

AGENDA

Day Two: April 10, 2024

New products for IBD patients—Funding landscape and clinical trials

8:00–9:00 a.m.	Breakfast/Registration Welcome	Russ Wyborski, PhD <i>Director, IBD Ventures Investments</i>	Crohn's & Colitis Foundation
KEYNOTE—THE IBD INVESTMENT LANDSCAPE—CHALLENGES AND OPPORTUNITIES Moderator: Tom Shehab, MD			
9:00–9:45 a.m.	The IBD investment landscape—Challenges and Opportunities	Tom Shehab, MD <i>Managing Partner at Arboretum Ventures</i>	Arboretum Ventures

AGENDA

Day Two: April 10, 2024

TIME	TITLE	SPEAKER	AFFILIATION
9:45-10:15 a.m.	Panel: Funding Landscape in IBD	Panel Participants Matt Hulsizer , <i>Co-Founder and Managing Partner of PEAK6 Investments</i> ; Julie Di Paolo, PhD , <i>J&J Boston Innovation Center</i> ; Caleb Bell, PhD , <i>Venture Partner at Corundum Systems Biology</i> ; Yaniv Sneor , <i>Founder of MABA—Mid Atlantic Bio Angels</i> ; Ricardo dos Santos, PhD , <i>Head of Venture Studio at Takeda Digital Ventures</i> Moderator: Tom Shehab, MD	
10:15-10:30 a.m.	Q&A with panelists		
10:30-10:45 a.m.	Break/Networking		
10:45 a.m.- 12:00 p.m.	SESSION 4: IBD Innovate Shark Tank	Introduction: Tom Shehab, MD	
10:45-11:00 a.m.	Advancing IBD management: flare tracking & AI progression insights	Sriram Muthukumar, PhD <i>CEO & Co-Founder</i>	EnLiSense
11:00-11:15 a.m.	Leveraging AI and digital pathology for quantification of epithelial biomarkers to improve diagnosis and treatment of IBD	Juliana Woda, PhD <i>Senior Director</i>	Mobius Care LLC
11:15-11:30 a.m.	Exosomm: Leading a new era of therapeutic food	Netta Granot, MBA <i>CEO & Co-Founder</i>	Exosomm
11:30-11:45 a.m.	Virtual complementary digestive care	Sam Jactel, MBA <i>Founder & CEO</i>	Ayble Health
11:45 a.m.- 12:00 p.m.	Robotic enteroscope for Crohn's disease	Yan Zhao, MD, PhD <i>Founder & CEO</i>	Drive Medical
12:00-1:30 p.m.	Lunch and networking		
	SESSION 5: Clinical Trials in IBD: Current challenges and opportunities	Moderator: Florian Rieder, MD	
1:30-2:15 p.m.	Current challenges and opportunities for IBD trials	Alan Moss, MD <i>Chief Scientific Officer</i>	Crohn's & Colitis Foundation
2:15-3:00 p.m.	Clinical Trials Panel	Panel Participants Alan Moss, MD ; Randall Pellish, MD , <i>Director, Lahey Inflammatory Bowel Disease Center</i> ; Mahalakshmi Parakala , <i>Patient representative, Clinical Research Coordinator, Boston Children's Hospital</i>	
3:00-3:30 p.m.	IBD Plexus	Ben Kostiuk, PhD <i>Associate Director, Life Science Partnerships, IBD Plexus</i>	Crohn's & Colitis Foundation
3:30-4:00 p.m.	IBD Innovate Shark Tank winner announcement		
3:30-4:00 p.m.	Meeting wrap-up and networking		

POSTERS

April 9, 2024

POSTER	ORGANIZATION	CATEGORY	PRESENTER	POSTER TITLE
1	3-D Matrix Europe (Puramatrix)	Therapeutic	Sharanya Sankar, PhD	Self-assembling peptide technology for precision drug delivery and mucosal healing in intestinal bowel disease
2	Onco Precision	Therapeutic	Robin Bruno, PharmD	Unveiling the strong safety profile and high target engagement of OPM-101, a first-in-class orally available RIPK2 inhibitor, in healthy volunteers, a phase 1 clinical trial
3	Seres Therapeutics	Microbiome	Christopher Ford, PhD	Candidate biomarkers of microbiome disruption for patient selection or stratification in clinical trials of microbiome therapeutics in IBD
4	Vedanta	Microbiome	Amanda Prince, PhD	Defined bacterial consortium as a therapeutic for inflammatory bowel disease
5	Microbiotica	Microbiome	Adam Wilkinson, PhD	Mechanistic understanding of MB310—a bacterial consortium for the treatment of ulcerative colitis
6	Johns Hopkins University	Device	Florin Selaru, MD, MBA	Development of a locally administered, sustained release antifibrotic for anastomotic strictures in Crohn's disease
7	NIBEC	Therapeutic	Beom Soo Jo, PhD	Epithelial regeneration by novel synthetic peptide (NP-201) for the treatment of IBD
8	Nexys Therapeutics	Therapeutic	Tom Wu, PhD	Gut restricted AhR agonist for the treatment of inflammatory bowel diseases
9	Lankenau Institute for Medical Research	Therapeutic	Sunil Thomas, PhD	Development of a mRNA-based therapy for ulcerative colitis

POSTERS

April 10, 2024

POSTER	ORGANIZATION	CATEGORY	PRESENTER	POSTER TITLE
10	Pragma Bio	Therapeutic	Orly Levitan, PhD	Unraveling gut-derived molecules for innovative IBD therapeutics
11	Aluda Pharmaceuticals	Therapeutic	Deebie Symmes, MBA	ALD-R491, an oral small molecule targeting vimentin, shows new actions and high-efficacy profile against severe IBD features, including fibrosis, inflammation, barrier repair, and dysbiosis
12	Evinature	Botanical Therapeutic	Nir Salomon, CHb	CurQD: A breakthrough nutraceutical for IBD therapy
13	Azora Therapeutics	Therapeutic	Matt Davidson, PhD	AT177: A first-in-class oral aryl hydrocarbon receptor (AhR) agonist for ulcerative colitis
14	Altis Biosystems	Platform	Maureen Bunger, PhD, MBA	Recapitulating inflammatory signaling pathways using an in vitro model of gastrointestinal epithelium
15	PathAI	AI/ Therapeutic	Fedaa Najdawi, MD	Machine learning-derived histological features of epithelial injury and repair in ulcerative colitis biopsies correlate with disease severity
16	Evotec	Therapeutic	Manjula Donepudi, PhD	Navigating IBD with Evotec: From discovery to cure
17	Organoid Sciences	Platform	Kyung Jin Lee, PhD	The next revolutionizing treatment for refractory IBD ulcers: The promise of organoid-based regenerative medicine

This conference is generously supported, in part, by:



Our vision is to transform preclinical therapeutic development with best-in-class human cell-based model systems of the intestine. Our RepliGut® Systems are a series of intestinal epithelium models derived from regional specific adult stem cells for improving functional and mechanistic insights of new and emerging IBD therapeutics.



Azenta's leading capabilities across multiomics services, cryogenic storage, automation, and informatics are dedicated to sample exploration and management. Azenta helps our customers bring impactful breakthroughs and therapies to market with greater speed and precision.



Taconic Biosciences offers access to three major classes of IBD mouse models, sold with full use rights for drug discovery and development. As the in vivo microbiome leader, Taconic offers the most options for investigating the microbiome as it relates to IBD.



CROHN'S & COLITIS FOUNDATION

733 Third Avenue, Suite 510, New York, NY 10017
www.crohnscolitisfoundation.org • 800-932-2423